Arthralgia

18

Pipeline Programs↗

2

Active Trials↗

12

Companies Involved↗

Arthralgia is an emerging landscape with 18 programs across 12 companies. The most active players are Eli Lilly, Jazz Pharmaceuticals, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 8 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

44/100

Completion Rate

71/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Eli Lilly

1 program

Jazz Pharmaceuticals

1 program

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Taiwan Bio Therapeutics Inc.

1 program

Bristol-Myers Squibb

1 program

Auxilium

1 program

Pipeline

Programs by Phase

Preclinical3

Dexketoprofen

Pamukkale University

Anastrozole

Istituto Clinico Humanitas

Letrozole

Novartis

Phase 1

No programs

Phase 25

Estrogen

Eli Lilly

Methotrexate

Alnylam Pharmaceuticals

Cannabidiol

Jazz Pharmaceuticals

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conjugated Equine Estrogen

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 32

Abatacept

Bristol-Myers Squibb

Testosterone

Auxilium

Approved8

Naproxen

Alnylam Pharmaceuticals

Capsaicin

Averitas Pharma, Inc.

Ketoprofen

Wyeth-Lederle Vaccines

Flurbiprofen

Pharmacia and Upjohn

Methylprednisolone

Pfizer

Analysis

Modality Breakdown

95%

Small molecule

21 of 22 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

11

clinical trials

Completed5 · 45%

Unknown status2 · 18%

Recruiting2 · 18%

Withdrawn1 · 9%

Terminated1 · 9%

Clinical Trials

Trial Activity

11 trials

Topical Treatment for TMJ Arthralgia

Recruiting·UUniversity of the Pacific·Phase 3·NCT05816226·90 enrolled

The MUSE Study for Menopausal Arthralgia

Recruiting·NNational University Hospital, Singapore·Phase 2/3·NCT06530459·100 enrolled

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT04754399·40 enrolled

Vitamin D3 for Aromatase Inhibitor Induced Arthralgias

Completed·—·Phase 2·NCT00867217·160 enrolled

Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT02778906·98 enrolled

Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone

Completed·UUppsala University·Phase 4·NCT01995019·56 enrolled

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

Completed·Alliance for Clinical Trials in Oncology·Phase 3·NCT01573442·227 enrolled

Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)

Terminated·AAHS Cancer Control Alberta·Phase 2·NCT06001125·27 enrolled

Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias

Withdrawn·—·Phase 2·NCT03384095

Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 2·NCT02838576·72 enrolled

Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia

Unknown status·—·Phase 2·NCT02024568·38 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)